P&G

Procter & Gamble's Q1 organic beauty sales rose 5% to $4.4B, with grooming sales up 5% to $1.9B. CFO Andre Schulten highlighted growth in Pantene Abundant & Strong and plans to improve underperforming categories. P&G aims to accelerate growth in China, currently in 'reinvention' phase.

Procter & Gamble reported 2026 revenue of $23.28B, up 4% YoY, and net income of $4.76B, down 0.5% YoY. EPS rose 1% to $1.97. The company announced a two-year restructuring plan and completed the $3.9B acquisition of Thorne.

Procter & Gamble (PG) shares rose 6% after reporting fiscal Q1 core EPS of $2.00 and revenue of $23.3B, both exceeding estimates. Growth was driven by higher volume, indicating strong demand. P&G increased its expected commodity cost hit to $1.4B for fiscal 2027 but maintained its core EPS guidance of $6.89-$7.11.

Procter & Gamble (PG) reported a 4% sales increase to $23.3B in Q1, driven by volume growth. Shares rose 5.62% to $165.65. Earnings grew 1% to $1.97 per share, but higher costs impacted margins. Operating cash flow was $5.8B, supporting dividends and buybacks. The stock trades near its GF Value estimate.

P&G (PG) reported Q1 2027 earnings with organic sales growth across all 10 product categories and 6 regions. North America and Europe grew 3% and 4% respectively, while Greater China saw 8% growth. Core EPS was $2, down 1 point YoY. The company maintained guidance for fiscal 2027 and highlighted successful product launches like Pantene's Abundant and Strong, Pampers Amoira, and Fairy Dish.

Procter & Gamble reported Q1 2027 organic sales growth of 4.0%, driven by volume increases and strategic interventions. Market share improved in the U.S. and China, with the latter benefiting from competitive dynamics. The company maintained fiscal 2027 guidance for 1%-3% organic sales growth, despite a $1.4 billion after-tax headwind from raw materials and energy. Management expects sequential acceleration in sales growth and plans to offset costs through productivity gains and pricing actions.